

IN THE CLAIMS:

Please substitute the following listing of claims for the previous listing of claims.

1. (Currently amended) A method for the pulmonary administration of inhalation of a dry powder drug composition from a passive dry powder inhaler to the respiratory tract of a patient, the method comprising:
providing a dry powder drug composition comprising particles comprising a lipid matrix and a particle size of 1-30 microns, mass median aerodynamic diameter of less than 5 microns, and bulk density of less than 0.5 g/cm³;
loading the drug composition into a passive dry powder inhaler having a resistance of from 0.01 to 0.30 (cmH₂O)^{1/2}/Lmin⁻¹; and
administering inhaling the drug composition from the inhaler to the respiratory tract of a patient,
wherein the emitted dose is at least 60% for flow rates from 10 to 60 liters per minute.
2. (Cancelled.)
3. (Previously amended) A method according to claim 2 wherein the emitted dose is at least 80% for flow rates from 10 to 60 liters per minute.
4. (Previously amended) A method according to claim 1 wherein the fine particle fraction is at least 60%.

5. (Previously amended) A method according to claim 1 wherein the lipid comprises a phospholipid selected from the group consisting of dipalmitoylphosphatidylcholine, distearylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerol, short-chain phosphatidylcholines, long-chain saturated phosphatidylethanolamines, long-chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, and long-chain saturated phosphatidylinositols.

6-10. (Cancelled.)

11. (Previously amended) A method according to claim 1 wherein the lung deposition is greater than 25%.

12. (Original) A method according to claim 1 wherein the lung deposition is greater than 30%.

13. (Original) A method according to claim 1 wherein the lung deposition is greater than 50%.

14. (Original) A method according to claim 1 wherein the drug selected from the group consisting of budesonide, tobramycin sulfate, leuprolide acetate, Amphotericin B and PTH.

15. (Previously amended) A method according to claim 1 wherein the powder comprises hollow porous microparticles.

16-20. (Cancelled).